These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 34207359)

  • 21. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.
    Ha H; Nam AR; Bang JH; Park JE; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ; Oh DY
    Oncotarget; 2016 Nov; 7(47):76604-76612. PubMed ID: 27780932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer.
    Rizzo A; Ricci AD; Brandi G
    Expert Opin Investig Drugs; 2021 Apr; 30(4):343-350. PubMed ID: 33645367
    [No Abstract]   [Full Text] [Related]  

  • 23. Evaluation of circulating PD-1 and PD-L1 as diagnostic biomarkers in dogs with tumors.
    Song DW; Ro WB; Park HM
    J Vet Sci; 2021 Sep; 22(5):e75. PubMed ID: 34553519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
    Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma.
    Fontugne J; Augustin J; Pujals A; Compagnon P; Rousseau B; Luciani A; Tournigand C; Cherqui D; Azoulay D; Pawlotsky JM; Calderaro J
    Oncotarget; 2017 Apr; 8(15):24644-24651. PubMed ID: 28445951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel serum marker for biliary tract cancer: diagnostic and prognostic values of quantitative evaluation of serum mucin 5AC (MUC5AC).
    Ruzzenente A; Iacono C; Conci S; Bertuzzo F; Salvagno G; Ruzzenente O; Campagnaro T; Valdegamberi A; Pachera S; Bagante F; Guglielmi A
    Surgery; 2014 Apr; 155(4):633-9. PubMed ID: 24468034
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
    Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
    Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Expression of Programmed Death-Ligand 1 on Immune Cells Is Related to a Better Prognosis in Biliary Tract Cancer.
    Kwon SC; Bang S; Park YN; Park JH; Kim SJ; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Park E; Lee HS
    Gut Liver; 2023 Nov; 17(6):933-941. PubMed ID: 36510775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical management of biliary tract cancers.
    Fairweather M; Balachandran VP; D'Angelica MI
    Chin Clin Oncol; 2016 Oct; 5(5):63. PubMed ID: 27829277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer.
    Chatterjee J; Dai W; Aziz NHA; Teo PY; Wahba J; Phelps DL; Maine CJ; Whilding LM; Dina R; Trevisan G; Flower KJ; George AJT; Ghaem-Maghami S
    Clin Cancer Res; 2017 Jul; 23(13):3453-3460. PubMed ID: 27986748
    [No Abstract]   [Full Text] [Related]  

  • 31. Golgi Protein 73 (GP73) Serum Levels Predict Outcome after Resection of Biliary Tract Cancer.
    Loosen SH; Halpaap J; Labuhn S; Bednarsch J; Alizai PH; Roeth AA; Lang SA; Vucur M; Kather JN; Knoefel WT; Ulmer TF; Neumann UP; Roderburg C; Luedde T
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
    Akamine T; Takada K; Toyokawa G; Kinoshita F; Matsubara T; Kozuma Y; Haratake N; Takamori S; Hirai F; Tagawa T; Okamoto T; Yoneshima Y; Okamoto I; Shimokawa M; Oda Y; Nakanishi Y; Maehara Y
    Surg Oncol; 2018 Mar; 27(1):88-94. PubMed ID: 29549910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns and genomic correlates of PD-L1 expression in patients with biliary tract cancers.
    Mody K; Starr J; Saul M; Poorman K; Weinberg BA; Salem ME; VanderWalde A; Shields AF
    J Gastrointest Oncol; 2019 Dec; 10(6):1099-1109. PubMed ID: 31949927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The present roles and future perspectives of Interleukin-6 in biliary tract cancer.
    Zhou M; Na R; Lai S; Guo Y; Shi J; Nie J; Zhang S; Wang Y; Zheng T
    Cytokine; 2023 Sep; 169():156271. PubMed ID: 37331095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Inflammation-based Prognostic Scores in Patients With Biliary Tract Cancer After Surgical Resection.
    Utsumi M; Kitada K; Tokunaga N; Yoshida Y; Narusaka T; Hamano R; Miyasou H; Tsunemitsu Y; Otsuka S; Inagaki M
    Anticancer Res; 2021 Apr; 41(4):2147-2155. PubMed ID: 33813426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
    Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C
    Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Programmed death ligand-1, tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients: Possible immunotherapy implications.
    Yu F; Gong L; Mo Z; Wang W; Wu M; Yang J; Zhang Q; Li L; Yao J; Dong J
    Biosci Trends; 2019 Mar; 13(1):58-69. PubMed ID: 30773525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer.
    Ruggieri AN; Yarchoan M; Goyal S; Liu Y; Sharon E; Chen HX; Olson BM; Paulos CM; El-Rayes BF; Maithel SK; Azad NS; Lesinski GB
    Clin Cancer Res; 2022 Oct; 28(19):4336-4345. PubMed ID: 35833954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach.
    Janvilisri T; Leelawat K; Roytrakul S; Paemanee A; Tohtong R
    Dis Markers; 2015; 2015():105358. PubMed ID: 26060332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.
    Tian L; Ma J; Ma L; Zheng B; Liu L; Song D; Wang Y; Zhang Z; Gao Q; Song K; Wang X
    World J Surg Oncol; 2020 Nov; 18(1):303. PubMed ID: 33228682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.